X-Linked Retinitis Pigmentosa Pipeline Insight Report 2023 (Updated)

(Albany, United States) As per DelveInsight's assessment, globally, the X-Linked Retinitis Pigmentosa Pipeline constitutes 5+ key companies continuously working towards developing 5+ X-Linked Retinitis Pigmentosa Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the X-Linked Retinitis Pigmentosa Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, X-Linked Retinitis Pigmentosa NDA approvals (if any), and product development activities comprising the technology, X-Linked Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the X-Linked Retinitis Pigmentosa Pipeline treatment landscape of the report, click here @ X-Linked Retinitis Pigmentosa Pipeline Outlook- https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the X-Linked Retinitis Pigmentosa Pipeline Report
• DelveInsight's X-Linked Retinitis Pigmentosa Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading companies working in the X-Linked Retinitis Pigmentosa market include Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
• PromisingX-Linked Retinitis Pigmentosa Pipeline Therapies in the various stages of development include Genetic: AAV5-RPGR, AAV2/5-RPGR, FT-002, Docosahexaenoic Acid OR corn/Soy Oil placebo, and others.
• On May 2023, Frontera Therapeutics announced a study of Early Phase 1 clinical trials for FT-002. A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
• On June 2023, MeiraGTx UK II Ltd announced a study of phase 3 clinical trials for Genetic: AAV5-RPGR. A clinical trial of AAV5-RPGR vector for patients with X-linked retinitis pigmentosa (XLRP).
• On August 2023, Janssen Pharmaceutical K.K. announced a study of Phase 3 clinical trials for AAV5-hRKp.RPGR. The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. Retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).

X-Linked Retinitis Pigmentosa Overview
X-linked Retinitis Pigmentosa is a rare, hereditary progressive genetic disorder associated with the gene mutation in chromosome X of an individual. This disorder is characterized by the progressive degeneration of photoreceptor cells in the retina and gradually leading to peripheral vision loss.

For further information, refer to the detailed X-Linked Retinitis Pigmentosa Unmet Needs, click here for X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

X-Linked Retinitis Pigmentosa Emerging Drugs Profile
• BIIB 112 (NSR-RPGR): Biogen
• 4D-125: 4 D Molecular Therapeutics

X-Linked Retinitis Pigmentosa Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for X-linked Retinitis Pigmentosa. The companies which have their X-linked Retinitis Pigmentosa drug candidates in the mid to advanced stage, Phase II/III include, Biogen and others.

Request a sample and discover the recent advances in X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis and Medications, Click here for more details @ X-Linked Retinitis Pigmentosa Segmentation- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

X-Linked Retinitis Pigmentosa Drugs and Companies
• Genetic: AAV5-RPGR: MeiraGTx UK II Ltd
• FT-002: Frontera Therapeutics
• Docosahexaenoic Acid OR Corn/Soy Oil Placebo: Retina Foundation of the Southwest/ DSM Nutritional Products Inc.

X-Linked Retinitis Pigmentosa Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the X-Linked Retinitis Pigmentosa Therapeutics Market include-
Biogen, 4D Molecular Therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.

Dive deep into rich insights for drugs for the X-Linked Retinitis Pigmentosa Pipeline, Click here @ X-Linked Retinitis Pigmentosa Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the X-Linked Retinitis Pigmentosa Pipeline Report
• Coverage- Global
• Companies- Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
• Therapies- Genetic: AAV5-RPGR, AAV2/5-RPGR, FT-002, Docosahexaenoic Acid OR corn/Soy Oil placebo, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on X-Linked Retinitis Pigmentosa Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. X-linked Retinitis Pigmentosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. X-linked Retinitis Pigmentosa - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. X-linked Retinitis Pigmentosa Collaboration Deals
9. Late Stage Products (Phase II/III)
10. BIIB 112 (NSR-RPGR): Biogen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase I/II)
13. 4D-125: 4 D Molecular Therapeutics
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. X-linked Retinitis Pigmentosa Key Companies
19. X-linked Retinitis Pigmentosa Key Products
20. X-linked Retinitis Pigmentosa- Unmet Needs
21. X-linked Retinitis Pigmentosa- Market Drivers and Barriers
22. X-linked Retinitis Pigmentosa- Future Perspectives and Conclusion
23. X-linked Retinitis Pigmentosa Analyst Views
24. X-linked Retinitis Pigmentosa Key Companies
25. Appendix

Important Published Links

https://logcworld.mn.co/posts/46134506
https://marketingops.mn.co/posts/46134636
https://motorcycle-events.mn.co/posts/46134899
https://intuitive-schooling.mn.co/posts/46135011
https://plenty-of-heathens.mn.co/posts/advancements-and-market-trends-in-langerhans-cell-histiocytosis-treatment
https://shopsanity.mn.co/posts/understanding-the-langerhans-cell-histiocytosis-market-current-landscape-and-future-prospects
https://mccoterie.mn.co/posts/46135751
https://go02100.mn.co/posts/46136119
https://freesaloneducation.mn.co/posts/46136215
https://sokomtaani.mn.co/posts/46136615
https://skillcrush.mn.co/posts/46136691
https://advicehonest.mn.co/posts/46136795
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/45816438
https://council-of-light.mn.co/posts/45816468
https://chanspirations.mn.co/posts/45816726
https://hulu-com-forgot.mn.co/posts/45816832
https://bucketseems-news.mn.co/members/20271966
https://sentinels.mn.co/members/20272156
https://akademe.mn.co/posts/navigating-the-acne-vulgaris-market-trends-treatments-and-technological-advances
https://tc-2345.mn.co/posts/45818004
https://gene-keys-genealogy.mn.co/posts/45818150
https://take-your-phone.mn.co/posts/45818381
https://digitaldrip.mn.co/posts/45818561
https://network-24921.mn.co/posts/45818644
https://friends-of-zizira.mn.co/members/20272206
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.